This phase 3 trial investigated the efficacy of tralokinumab monotherapy in pediatric patients with moderate-to-severe atopic dermatitis (AD). The study found that tralokinumab had superior efficacy compared with placebo for primary and secondary endpoints, with improvements seen in key psychosocial and symptomatic effects of AD at Week 16. While not all patients achieved the full clinical benefit at Week 16, those who did achieve clinical responses without rescue medication maintained their responses through Week 52. The study suggests that targeting IL-13 alone can improve multiple high-effect disease domains in pediatric patients with AD, and most patients are likely to respond to tralokinumab, consistent with the predominance of cutaneous IL-13 expression in AD phenotypes.
Reference: Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. [published online ahead of print, 2023 Apr 19]. JAMA Dermatol. 2023;e230627. doi:10.1001/jamadermatol.2023.0627
Link: https://jamanetwork.com/journals/jamadermatology/fullarticle/2804014?resultClick=1
